Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DA-22-004

Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed)

Closed on August 10, 2022.

Posted
February 2, 2021
Close date
August 10, 2022
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $570,279 in first-year total cost, median $570,279.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 LXF-C (J2)]1

Most frequent institutions

  1. DREXEL UNIVERSITY1
Competing awards under RFA-DA-22-004 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Defining molecular mechanisms by which stimulant evoked dopamine drives inflammation and neuronal dysfunction in neuroHIV1R61DA058501-01GASKILL, PETER JESSEDREXEL UNIVERSITY, PA$570,279ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DA-22-004: Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) | ScienceDex | ConductScience